BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease. (April 2016)

• Record Type: Journal Article
• Authors: Scannevin, Robert H.; Chollate, Sowmya; Brennan, Melanie S.; Snodgrass-Belt, Pamela A.; Peng, Hairuo; Xu, Lin; Jung, Mi-young; Bussiere, Thierry; Arastu, Mahin F.; Talreja, Tina; Xin, Zhili; Dunstan, Robert W.; Fahrer, Diana; Rohde, Ellen; Dunah, Anthone W.; Wang, Joy; Kumaravel, Gnanasambandam; Taveras, Arthur G.; Moore Arnold, H.; Rhodes, Kenneth J.
• Is Part Of: Neuropharmacology. Volume 103(2016)
• Page Start: 57
• Page End: 68
• Publication Date: 2016-04
• Subjects: Amyloid β -- γ-Secretase -- γ-Secretase modulator -- Alzheimer's disease -- Amyloid precursor protein; Neuropsychopharmacology -- Periodicals; Autonomic Agents -- Periodicals; Neuropsychopharmacologie -- Périodiques; Neuropsychopharmacology; Periodicals; Electronic journals; 615.78
• DOI: 10.1016/j.neuropharm.2015.12.006
• Languages: English
• ISSNs: 0028-3908

Abstract

Abstract: Reducing the production of larger aggregation-prone amyloid β-peptides (Aβ) remains an untested therapeutic approach for reducing the appearance and growth of Aβ plaques in the brain, which are a hallmark pathological feature of Alzheimer's disease. γ-Secretase modulators (GSMs) are therapeutics that impact γ-secretase-dependent cleavage of amyloid precursor protein to promote the production of shorter Aβ peptides that are less prone to aggregation and plaque deposition. This is accomplished without inhibiting overall γ-secretase function and cleavage of other substrates, which is believed to be a source of deleterious side effects. Here, we report the pharmacokinetic and pharmacodynamic properties of BIIB042, a novel bioavailable and brain-penetrant GSM. In cell-based assays, BIIB042 reduced the levels of Aβ42, increased the levels of Aβ38 and had little effect on the levels of Aβ40, the most abundant Aβ species. Similar pharmacodynamic properties were confirmed in the central nervous system and in plasma of mice and rats, and also in plasma of cynomolgus monkeys after a single oral dose of BIIB042. BIIB042 reduced Aβ42 levels and Aβ plaque burden in Tg2576 mice, which overexpress human amyloid precursor protein and serve as a model system for Alzheimer's disease. BIIB042 did not inhibit cleavage of other γ-secretase substrates in cell-based and in vivo signaling and cleavage assays. The pharmacodynamic effects of lowering Aβ42 in the central nervous system coupled with demonstrated efficacy in reducing plaque pathology suggests modulation of γ-secretase, with molecules like BIIB042, is a compelling therapeutic approach for the treatment of Alzheimer's disease. Highlights: Longer amyloid peptides (Aβ42) are thought to by pathogenic in Alzheimer's disease. γ-Secretase modulators selectively reduce pathogenic Aβ isoforms like Aβ42. BIIB042 is a potent, brain penetrant γ-secretase modulator. BIIB042 reduced Aβ42 levels in cell models, rodents and cynomolgus monkeys. BIIB042 reduced plaque pathology in a mouse transgenic model of Alzheimer's disease.